<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04370652</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0202</org_study_id>
    <nct_id>NCT04370652</nct_id>
  </id_info>
  <brief_title>Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum</brief_title>
  <official_title>Medical Treatment of Peyronie's Disease With Collagenase Clostridium Histolyticum (CCH or Xiapex®): Sexual and Psychological Impact and Results From 156 Patients' Questionnaires Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peyronie's disease is the appearance of a fibrosis plaque on the albuginea of the corpora
      cavernosa, which produces mechanical traction at the time of erection, inducing a
      deformation/curvature of the erect penis. The physiopathology is largely unknown.

      There is a significant sexual and psychological impact on patients. Historically, the only
      possible treatment was surgical. The only drug treatment that was FDA approved for this
      disease was Collagenase from Clostridium Histolyticum marketed under the name Xiapex® until
      31/12/2019 by Sobi laboratory. Marketing was stopped on that date for economic reasons and
      restricted to the US market only.

      The investigators propose a retrospective evaluation of the largest French monocentric series
      of this treatment from the perspective of the sexual and psychological evaluation of
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Peyronie's Disease Questionnaire (PDQ)</measure>
    <time_frame>every 4 weeks for 2 years</time_frame>
    <description>Peyronie's Disease Questionnaire (PDQ) : Change in baseline Peyronie's Disease Questionnaire Score each 4 weeks, i.e. before each new injection ; for up 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Penile curvature angulation</measure>
    <time_frame>every 4 weeks for 2 years</time_frame>
    <description>Penile curvature angulation : Change in baseline penile curvature angulation each 4 weeks, i.e. before each new injection ; for up 2 years</description>
  </secondary_outcome>
  <enrollment type="Actual">156</enrollment>
  <condition>Peyronie Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Peyronie's disease stable for more than 3 months after 12 to 18 months of evolution
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age ≥ 18 years old

          -  Peyronie's disease stable for more than 3 months after 12 to 18 months of evolution

          -  Angle of penis deformation ≥ 30°

        Exclusion criteria:

          -  Surgery for Peyronie's disease before

          -  Anticoagulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edouard Fortier, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Collagenase Clostridium Histolyticum</keyword>
  <keyword>Xiapex®</keyword>
  <keyword>Peyronie's Disease Questionnaire (PDQ)</keyword>
  <keyword>Sexual dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penile Induration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

